Thanks to the Metalquimia Foundation, a member of Fundación Empresas IQS, the university center has acquired a Flow Cytometer unit, very useful in laboratories for the development of new formulations in the field of biomedicine.

On May 9, the institutional act took place at IQS, attended by Josep Lagares, CEO of Metalquimia and IQS alumni, Mrs. Marta Mir, and Eulàlia Tomàs, director, of the Metalquimia Foundation; and on behalf of IQS, Dr. Salvador Borros, General Director and Rosa Curt, Director of Fundación Empresas IQS.

With the acquisition of the Flow Cytometer, the Materials Engineering Group (GEMAT), which is investigating the development of new controlled drug release systems to respond to unmet medical needs, will be able to benefit from the new equipment. This will make it possible to speed up the studies and make them more cost-effective, thus speeding up the arrival of new formulations in clinical phases.

Among other aspects, the cytometers allow the study of cell viability, to ensure that the formulations do not produce toxicity; the cell cycle, to see the effect that a treatment can have on secular reproduction; or the state of cell differentiation, important for regeneration studies.